Watson Pharm receives FDA final approval for Generic Wellbutrin XL 300 Mg

Co announced that it has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for bupropion hydrochloride extended-release tablets, 300 mg. Bupropion hydrochloride extended-release is the generic equivalent to GlaxoSmithKline's Wellbutrin XL tablets, which is indicated for the treatment of major depressive disorder. The Co intends to launch the product immediately.